SpaceX stock climbs to highest since June, returning Musk to trillionaire status

SpaceX shares rose nearly 8% Monday to $171.09 after Morgan Stanley called the stock “cheap,” recommended buying, and set a $300 price target—about 75% above that close. Analysts cited Starship progress, future AI releases, and neocloud contracts; a successful upper-stage ship catch could be a major catalyst, ahead of a test flight and Q3 earnings expected in late October. Shares have gained about 58% since bottoming in early August, while the article also notes Grok trails leading AI models and SpaceX earns revenue from renting AI capacity.

Analysis

The rally is increasingly an execution-and-expectations trade, not simply a launch-services re-rating. A successful Starship recovery would improve the long-run economics of satellite deployment and expand addressable payload demand, but one dramatic test is not evidence of repeatable cadence, operating cost, or regulatory clearance. A failed recovery—or a delay—could therefore unwind near-term catalyst premium faster than it damages the underlying launch franchise.

AI is the less-underwritten leg: renting capacity to outside model developers can monetize infrastructure before Grok wins users, but the durability depends on utilization, customer concentration, power and capital costs, and whether acquisitions integrate into a coherent offering. The orbital-chip demonstration should not be treated as proof that space-based compute is commercially economical. For Alphabet, capacity access could be useful while also making it a customer of a potential infrastructure competitor; the net effect is not clearly directional. Meta faces no direct implication established here.

The 1–3 month setup is binary around the next Starship test and earnings; 6–18 month value creation requires repeatable launches, customer-backed AI demand, and contract conversion. Defense relationships may support demand, but also concentrate political and procurement risk. The contrarian risk is that investors capitalize ambitious future options before operating evidence arrives. Verify launch cadence/recovery, AI revenue and utilization, capex, backlog, and contract economics before underwriting the valuation.

Key Decisions for Investors

• Avoid chasing SPCX solely on analyst enthusiasm or a single test-flight catalyst. For investors seeking event exposure, consider a defined-risk call spread only if pricing leaves acceptable downside and size it for a potentially sharp post-test reversal.
• Use the late-October results and next Starship test as evidence gates: require measurable progress on reusable recovery and disclosure of AI customer demand, utilization, and spending before adding to a longer-horizon position.
• Falsify the bullish execution thesis if recovery attempts repeatedly fail or slip, launch cadence does not improve, or AI capacity growth requires spending without corresponding utilization or customer commitments; reassess rather than assuming delays are immaterial.
• Track federal award flow and procurement/regulatory developments as both catalysts and downside risks. A change in administration support or contract awards could impair the defense narrative even if commercial launch demand remains intact.